SpringerOpen Newsletter

Receive periodic news and updates relating to SpringerOpen.

Open Access Open Badges Nano Express

Novel Strategy to Fabricate PLA/Au Nanocomposites as an Efficient Drug Carrier for Human Leukemia Cells in Vitro

Jingyuan Li1, Chen Chen1, Xuemei Wang1*, Zhongze Gu1 and Baoan Chen2

Author affiliations

1 State Key Lab of Bioelectronics (Chien-Shiung WU Laboratory), Southeast University, 210096 Nanjing, China

2 Department of Hematology, Zhongda Hospital, Southeast University, 210096 Nanjing, China

For all author emails, please log on.

Citation and License

Nanoscale Res Lett 2011, 6:29  doi:10.1007/s11671-010-9762-3

Published: 14 September 2010


Poly (lactic acid) (PLA) polymer has the promising applications in the biomedical field because of its biodegradability and safe elimination. In this study, we have explored the bio-application of new nanocomposites composed with PLA nanofibers and Au nanoparticles as the potential drug carrier for an efficient drug delivery in target cancer cells. The results demonstrated that the anticancer drug daunorubicin could be efficiently self-assembled on the surface of PLA/Au nanocomposites and the synergistic enhancement of PLA/Au nanocomposites conjugated with daunorubicin into drug-sensitive K562 and drug-resistant leukemia K562/AO2 cells could be obviously observed by MTT assay and confocal fluorescence microscopy studies. These observations suggest that the new nanocomposites could readily induce daunorubicin to accumulate and uptake in target leukemia cells and increase the drug's cytotoxicity. Especially, the PLA/Au nanocomposites could significantly facilitate the cellular drug absorbtion of daunorubicin into drug-resistant K562/AO2 cells and efficiently inhibit the cancer cell proliferation. This raised the possibility to utilize the PLA/Au nanocomposites as a new effective additive agent to inhibit the drug resistance and thus as a novel strategy to sensitively track the respective cancer cells.

Human leukemia; PLA/Au nanocomposites; Daunorubicin; Drug delivery; Multidrug resistance